ProtAffin is a biotechnology company developing a novel class of biopharmaceuticals based on glycan-binding decoy proteins

Financing > Overview

ProtAffin is supported by a strong syndicate of international venture capital investors. ProtAffin raised a €4 million Series A financing round in 2007, led by Aescap Venture Management BV (Amsterdam, The Netherlands), with participation from Z-Cube Srl, the corporate venture arm of the Zambon Pharmaceutical Group (Milan, Italy) and The Entrepreneurs Fund (London, UK).

The Company raised a €14.1 million Series B financing round in April 2009, co-led by Atlas Venture and SR One Ltd., the corporate investment fund for GlaxoSmithKline plc and by existing investors.

ProtAffin has also received €2 million Seed Finance and Grant finance from Austria Wirtschaftsservice (aws) and Förschungsförderungsgesellschaft (FFG) in Vienna, Austria and from Steirische Förderungsgesellschaft (SFG) in Graz, Austria.

Additional investors interested in supporting ProtAffin through the next stage of company growth should contact Dr. Jason Slingsby, CEO (.(JavaScript must be enabled to view this email address)).